What does AIRE mean in UNCLASSIFIED
AIRE (Acute Infarction Ramipril Efficacy) is a clinical trial designed to evaluate the effectiveness and safety of ramipril, an angiotensin-converting enzyme (ACE) inhibitor, in reducing mortality and major cardiovascular events in patients who have recently experienced acute myocardial infarction (heart attack).
AIRE meaning in Unclassified in Miscellaneous
AIRE mostly used in an acronym Unclassified in Category Miscellaneous that means Acute Infarction Ramipril Efficacy
Shorthand: AIRE,
Full Form: Acute Infarction Ramipril Efficacy
For more information of "Acute Infarction Ramipril Efficacy", see the section below.
Key Findings
The AIRE trial enrolled over 2,000 patients who were randomized to receive either ramipril or placebo. The primary outcome was death from any cause, non-fatal myocardial infarction, or stroke.
The results showed that ramipril significantly reduced the risk of the primary outcome by 16% compared to placebo.
- Ramipril also reduced the risk of:
- Death from cardiovascular causes by 22%
- Non-fatal myocardial infarction by 20%
- Stroke by 13%
Safety and Tolerability
Ramipril was generally well-tolerated. The most common side effects were hypotension, dizziness, cough, and headache. These side effects were usually mild and transient.
Essential Questions and Answers on Acute Infarction Ramipril Efficacy in "MISCELLANEOUS»UNFILED"
What is the AIRE study?
The AIRE study (Acute Infarction Ramipril Efficacy) was a large, randomized, double-blind, placebo-controlled trial that evaluated the efficacy and safety of ramipril in patients with acute myocardial infarction (heart attack).
What was the purpose of the AIRE study?
The purpose of the AIRE study was to determine whether ramipril, an ACE inhibitor, could reduce mortality and morbidity in patients with acute myocardial infarction.
What were the key findings of the AIRE study?
The AIRE study found that ramipril significantly reduced all-cause mortality, cardiovascular mortality, and hospitalizations for heart failure in patients with acute myocardial infarction. Ramipril was also well-tolerated, with a low incidence of side effects.
What are the implications of the AIRE study for clinical practice?
The AIRE study provides strong evidence that ramipril is an effective and safe treatment for patients with acute myocardial infarction. Ramipril should be considered for use in all patients with acute myocardial infarction, regardless of age, gender, or race.
What are the limitations of the AIRE study?
The AIRE study was conducted over 20 years ago, and some of the findings may not be applicable to current clinical practice. Additionally, the study was conducted in a relatively small number of patients, and the results may not be generalizable to all patients with acute myocardial infarction.
Final Words: The AIRE trial provides strong evidence that ramipril is an effective and safe treatment for patients who have recently experienced acute myocardial infarction.
Ramipril reduces the risk of death, non-fatal myocardial infarction, and stroke, and is well-tolerated.
Therefore, ramipril should be considered as a standard of care in the treatment of patients with acute myocardial infarction.